A poster with the title Anti-fibrotic effect of NV556, a sanglifehrin-based cyclophilin inhibitor, in a preclinical model of non-alcoholic steatohepatitis 1) will be presented at the conference and will provide an update on the development of the company’s compound NV556 for the treatment of NASH.
The International Liver Congress is the main annual scientific conference of EASL (European Association for the Study of the Liver), an event with about 11,000 attendees that gathers scientific and medical experts from around the world to share and discuss the latest liver research findings.
About NeuroVive’s NASH projects
NV556 is a potent cyclophilin inhibitor in NeuroVive’s Sangamide class of compounds. NV556 has undergone extensive preclinical development and showed an excellent safety profile. During autumn 2016, the first preclinical results were received for the effects of NV556 on fibrosis development in an experimental model of NASH.
In addition to NV556, NeuroVive is developing a new class of compounds with a different mode of action that may offer complementary treatment of NASH. This discovery project (NVP022) is based on NeuroVive’s core competence in mitochondrial energy regulation and the partner company Isomerase’s innovative chemistry capabilities.
Inflammation and excess fat in the liver are symptoms of non-alcoholic steatohepatitis (NASH), a condition that causes scarring of the liver which can lead to cirrhosis of the liver and liver cancer (hepatocellular carcinoma). There is a strong link between NASH and other metabolic disorders, such as diabetes and obesity. The disease is common all over the world and about 3-5% of all Americans (about 15 million people) suffer from NASH.2)There are currently no registered treatment options available.
About EASL and ILC
The European Association for the Study of the Liver (EASL) started as a small group of 70 hepatologists from 15 European countries who came together to share best medical practice in April 1966. Now EASL has evolved into a major European Association with international influence dedicated to the liver and liver disease. EASL has over 4,000 members from all over the world and provides an annual platform, The International Liver Congress™ (ILC), for liver experts to meet and discuss latest scientific research.
1) Grönberg Alvar, Elmér Eskil, Gregory Matthew, Moss Steven, Hansson Magnus (accepted abstract)
2) Vernon G. et al. Aliment Pharmacol Ther. 2011;34(3):274-85
NeuroVive Pharmaceutical AB is a leader in mitochondrial medicine. The company is committed to the discovery and development of medicines that preserve mitochondrial integrity and function in areas of unmet medical need. The company’s strategy is to take drugs for rare diseases through clinical development and into the market. The strategy for projects within larger indications outside the core focus area is out-licensing in the preclinical phase. NeuroVive enhances the value of its projects in an organization that includes strong international partnerships and a network of mitochondrial research institutions, as well as expertise with capacities within drug development and production.
NeuroVive has a project in early clinical phase II development for the prevention of moderate to severe traumatic brain injury (NeuroSTAT®). NeuroSTAT has orphan drug designation in Europe and in the US. The R&D portfolio consists of several late stage research programs in areas ranging from genetic mitochondrial disorders to cancer and metabolic diseases such as NASH.
NeuroVive is listed on Nasdaq Stockholm, Sweden (ticker: NVP). The share is also traded on the OTCQX Best Market in the US (OTC: NEVPF).
For investor relations and media questions, please contact:
Cecilia Hofvander, NeuroVive, Tel: +46 (0)46 275 62 21 or firstname.lastname@example.org
NeuroVive Pharmaceutical AB (publ)
Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46 275 62 20 (switchboard)
This information is information that NeuroVive Pharmaceutical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 10:00 a.m. CEST on 5 April, 2017.